Related Experiment Video
Updated: Apr 19, 2026
12:19
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
Published on: April 10, 2026
20
ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression
A Ray1, L Tennakoon1, J Keller1
1Department of Psychiatry, Stanford University, Stanford, CA, USA.
The Pharmacogenomics Journal
|December 10, 2014
Summary
Genetic variations in the ABCB1 gene influence treatment outcomes for major depression. Specific ABCB1 single nucleotide polymorphisms (SNPs) are linked to remission and side effects, suggesting potential for personalized depression treatment.
Area of Science:
- Pharmacogenetics
- Neuroscience
- Genetics
Background:
- The multidrug resistance-1 (MDR1 or ABCB1) gene encodes P-glycoprotein (P-gp), a crucial efflux pump at the blood-brain barrier.
- P-gp plays a significant role in the transport of various medications, including antidepressants, affecting their efficacy and side effect profiles.
Purpose of the Study:
- To investigate the association between allelic variations in the ABCB1 gene and treatment outcomes (remission and side effects) in patients with chronic major depression.
- To determine if specific single nucleotide polymorphisms (SNPs) in ABCB1 correlate with remission rates and the occurrence of side effects in patients treated with P-gp substrates.
Main Methods:
- Analysis of 6 ABCB1 single nucleotide polymorphisms (SNPs) in 83 patients from the REVAMP trial for chronic major depression.
- Genotyping was performed to assess the frequency and time to remission, as well as the average side effects across different genotype groups.
- Statistical analyses were conducted to control for the effects of other ABCB1 SNPs.
Main Results:
- All six investigated ABCB1 SNPs were significantly associated with remission and time to remission.
- Minor allele carriers of rs2235040 and rs9282564 showed statistically significant improvements in remission after controlling for other SNPs.
- Common homozygotes for rs2235040 and rs9282564 experienced significantly higher average side effects, even after controlling for other ABCB1 SNPs.
Conclusions:
- ABCB1 gene variations, particularly SNPs rs2235040 and rs9282564, are important predictors of treatment response and side effects in major depression.
- These findings support the potential utility of ABCB1 genotyping for developing personalized medicine strategies in the treatment of depression.
- Understanding ABCB1 variation can help optimize antidepressant selection and dosing to improve patient outcomes and minimize adverse events.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
168
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
168
01:23Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
01:21G-protein Coupled Receptors
134.9K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
134.9K
01:06Carrier-Mediated Transport
1.6K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.6K
01:25Antidepressant Drugs: Overview
2.2K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.2K